company background image
SGEN

SeagenNasdaqGS:SGEN Stock Report

Market Cap

US$28.9b

7D

-8.4%

1Y

-11.9%

Updated

02 Dec, 2021

Data

Company Financials +
SGEN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SGEN Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

Rewards

Trading at 52.4% below our estimate of its fair value

Earnings are forecast to grow 81.12% per year

Risk Analysis

No risks detected for SGEN from our risk checks.

Seagen Competitors

Amgen

NasdaqGS:AMGN

US$113.1b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$65.9b

Incyte

NasdaqGS:INCY

US$14.3b

Exelixis

NasdaqGS:EXEL

US$5.2b

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$158.67
52 Week HighUS$202.60
52 Week LowUS$133.20
Beta0.79
1 Month Change-12.09%
3 Month Change4.24%
1 Year Change-11.93%
3 Year Change155.75%
5 Year Change137.07%
Change since IPO1,823.27%

Recent News & Updates

Shareholder Returns

SGENUS BiotechsUS Market
7D-8.4%-1.4%-3.5%
1Y-11.9%1.8%19.4%

Return vs Industry: SGEN underperformed the US Biotechs industry which returned 2% over the past year.

Return vs Market: SGEN underperformed the US Market which returned 17.8% over the past year.

Price Volatility

Is SGEN's price volatile compared to industry and market?
SGEN volatility
SGEN Average Weekly Movement4.1%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: SGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: SGEN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,092Clay Siegallhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
SGEN fundamental statistics
Market CapUS$28.94b
Earnings (TTM)-US$332.75m
Revenue (TTM)US$1.75b

16.6x

P/S Ratio

-87.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGEN income statement (TTM)
RevenueUS$1.75b
Cost of RevenueUS$1.43b
Gross ProfitUS$318.62m
ExpensesUS$651.37m
Earnings-US$332.75m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.82
Gross Margin18.25%
Net Profit Margin-19.06%
Debt/Equity Ratio0%

How did SGEN perform over the long term?

See historical performance and comparison

Valuation

Is Seagen undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SGEN ($158.67) is trading below our estimate of fair value ($333.48)

Significantly Below Fair Value: SGEN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SGEN is overvalued based on its PB Ratio (9.2x) compared to the US Biotechs industry average (2.7x).


Future Growth

How is Seagen forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

81.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: SGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SGEN's is expected to become profitable in the next 3 years.

Revenue vs Market: SGEN's revenue (31.6% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: SGEN's revenue (31.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGEN's Return on Equity is forecast to be high in 3 years time (23.5%)


Past Performance

How has Seagen performed over the past 5 years?

36.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SGEN is currently unprofitable.

Growing Profit Margin: SGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 36.1% per year.

Accelerating Growth: Unable to compare SGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: SGEN has a negative Return on Equity (-10.51%), as it is currently unprofitable.


Financial Health

How is Seagen's financial position?


Financial Position Analysis

Short Term Liabilities: SGEN's short term assets ($3.1B) exceed its short term liabilities ($698.4M).

Long Term Liabilities: SGEN's short term assets ($3.1B) exceed its long term liabilities ($114.5M).


Debt to Equity History and Analysis

Debt Level: SGEN is debt free.

Reducing Debt: SGEN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SGEN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Seagen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average management tenure


CEO

Clay Siegall (60 yo)

19.08yrs

Tenure

US$16,493,557

Compensation

Dr. Clay B. Siegall, Ph D., co-founded Seagen Inc. (formerly known as Seattle Genetics, Inc.). in 1998 and has been its Chief Executive Officer since November 2002 and its President since June 2000. Dr. Si...


CEO Compensation Analysis

Compensation vs Market: Clay's total compensation ($USD16.49M) is above average for companies of similar size in the US market ($USD11.11M).

Compensation vs Earnings: Clay's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SGEN's management team is seasoned and experienced (6.1 years average tenure).


Board Members

Experienced Board: SGEN's board of directors are seasoned and experienced ( 14.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Seagen Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Seagen Inc.
  • Ticker: SGEN
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$28.937b
  • Shares outstanding: 182.86m
  • Website: https://www.seagen.com

Number of Employees


Location

  • Seagen Inc.
  • 21823 30th Drive SE
  • Bothell
  • Washington
  • 98021
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:30
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.